Japan's Ono Pharmaceutical gears up sales reps for Opdivo

Osaka-based Ono Pharmaceutical is gearing up its sales force to boost sales of Opdivo (nivolumab) as sales look set to pick up quickly from ¥2.5 billion ($21 million) at the end of March 2015 to past ¥100 billion annually in the coming years, Nikkei Asian Review reports. The drug is also sold by Bristol-Myers Squibb ($BMY), which acquired the originator company, Medarex. Ono secured Japan rights under a 2005 pact with Medarex; it has been approved there for unresectable melanoma since 2014. Nikkei said that the two companies now have a total of 300 sales reps aimed at around 1,000 key hospitals in Japan. Earlier this month, Ono said it would develop a new diagnostic tool to determine whether more patients will benefit from Opdivo. In April of last year, Ono filed for in-country approval of Opdivo to treat NSCLC and received manufacturing and marketing approval in December 2015. Report


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.